Use of COVID-19 Vaccines in the United States
Interim Clinical Considerations
Summary of recent changes (last updated June 24, 2022):
- New guidance for use of Moderna COVID-19 Vaccine in children and adolescents ages 6–17 years
Reference Materials
- Summary Document for Interim Clinical Considerations (Updated 6/24/2022)
- Interim COVID-19 Immunization Schedule (Updated 6/24/2022)
- At-A-Glance COVID-19 Vaccination Schedule (NEW 6/24/2022)
- Moderna COVID-19 Vaccine for Children who Transition from a Younger to Older Age Group (NEW 6/24/2022)
- Pfizer-BioNTech for Children who Transition from a Younger to Older Age Group (NEW 6/24/2022)
Get Email Updates
Receive email updates about this page.
COVID-19 Vaccines, Recommendations, and Schedules
Special Situations and Populations
Appendices
- People who received COVID-19 vaccine outside the United States (Appendix A)
- People who received COVID-19 vaccine as part of a clinical trial (Appendix B)
- Vaccine administration errors and deviations (Appendix C)
- Guidance for people who are moderately or severely immunocompromised and vaccinated with Janssen COVID-19 vaccine (Appendix D)
- Triage of people with a history of allergies or allergic reactions (Appendix E)
More about the Interim Clinical Considerations
See the FAQ page for answers to commonly asked questions about the Interim Clinical Considerations.
Page last reviewed: June 24, 2022
Content source: National Center for Immunization and Respiratory Diseases